Manel Merabet
Chief Development Officer SKYMAB Biotherapeutics
Dr. Manel Kraiem Merabet is Chief Development Officer at Skymab, with over 9 years of experience in translational and clinical oncology research. Formerly a senior project manager at Innate Pharma, she led ADC programs from lead optimization to IND, and is regarded as an ADC expert. Manel holds a PharmD, a PhD in Oncology and Immunology, a European radiopharmacy-radiobiology degree from CEA Saclay, and a Master?s in Organic Chemistry from Saint Jerome University. Merabet collaborates with leading biotech and pharma partners and has been recognized as an invited expert speaker at major ADC and oncology conferences, including the World ADC Summit.
Seminars
Tuesday 5th May 2026
Leveraging Tumour Resistance Models to Empower ADC Development & Overcome Resistance Mechanisms
2:30 pm
- Spotlighting the development of predictive preclinical resistance models
- Uncovering mechanistic insights into intrinsic and acquired resistance pathways
- Dissecting efficacy and linker properties using these models to improve the clinical translatability of ADC therapies
